Ipamorelin CJC-1295 Blend

The Ipamorelin + CJC-1295 Blend combines two complementary GH secretagogues in a single lyophilized formulation. Ipamorelin is a selective pentapeptide GH secretagogue receptor (GHSR) agonist, while CJC-1295 No DAC (Mod GRF 1-29) is a modified GHRH analog that activates the GHRH receptor on pituitary somatotrophs. This combination represents the most widely studied GH secretagogue pairing, based on the well-characterized synergistic interaction between GHRH and GHSR signaling at the pituitary level. When GHRH receptor activation (via CJC-1295) is combined with GHSR activation (via Ipamorelin), the resulting GH release is significantly greater than the additive effect of either peptide alone. Ipamorelin was chosen over other GHRPs for its selectivity — it releases GH without significant effects on cortisol, prolactin, or appetite.

The Ipamorelin + CJC-1295 Blend has been investigated for its synergistic activation of two distinct signaling cascades in pituitary somatotroph cells. CJC-1295 No DAC activates the GHRH receptor, a Gs-coupled GPCR that increases intracellular cAMP through adenylyl cyclase, activating PKA and promoting both GH gene transcription and secretory vesicle mobilization. Ipamorelin activates GHS-R1a, a Gq-coupled receptor that stimulates phospholipase C, IP3 generation, and intracellular calcium release. Studies demonstrate that the cAMP pathway (GHRH) and calcium/PKC pathway (GHSR) converge synergistically on GH exocytosis — the cAMP-mediated vesicle priming is amplified by calcium-triggered membrane fusion. Researchers observed that this dual-pathway activation produces GH peaks 2-5 times greater than either agonist alone. Ipamorelin’s selectivity ensures that this synergistic GH release occurs without significant activation of ACTH/cortisol or prolactin pathways.

GHRH-GHSR Synergy

Bowers et al. (1990) demonstrated the fundamental synergistic interaction between GHRH and GH secretagogues at the pituitary level, showing that combined administration produced supra-additive GH responses in both animal and human models [1].

Ipamorelin Selectivity

Raun et al. (1998) characterized ipamorelin as the first selective GH secretagogue, demonstrating GH release without significant effects on ACTH, cortisol, or prolactin at GH-maximizing doses [2].

Modified GRF Pharmacology

Ling et al. (1984) established that the first 29 amino acids of GHRH contain full biological activity and characterized substitutions that improve metabolic stability, forming the basis for the CJC-1295 component [3].